Palvella Therapeutics (PVLA) EBITDA (2016 - 2024)
Historic EBITDA for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$3.4 million.
- Palvella Therapeutics' EBITDA fell 10886.75% to -$3.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 19729.84%. This contributed to the annual value of -$17.4 million for FY2024, which is 19729.84% down from last year.
- Latest data reveals that Palvella Therapeutics reported EBITDA of -$3.4 million as of Q4 2024, which was down 10886.75% from -$7.0 million recorded in Q3 2024.
- Palvella Therapeutics' 5-year EBITDA high stood at $38.0 million for Q4 2023, and its period low was -$16.2 million during Q3 2021.
- Over the past 5 years, Palvella Therapeutics' median EBITDA value was -$7.9 million (recorded in 2022), while the average stood at -$5.7 million.
- Its EBITDA has fluctuated over the past 5 years, first crashed by 230567.01% in 2020, then skyrocketed by 52746.62% in 2023.
- Over the past 5 years, Palvella Therapeutics' EBITDA (Quarter) stood at -$13.9 million in 2020, then soared by 33.02% to -$9.3 million in 2021, then grew by 4.71% to -$8.9 million in 2022, then skyrocketed by 527.47% to $38.0 million in 2023, then crashed by 108.87% to -$3.4 million in 2024.
- Its EBITDA was -$3.4 million in Q4 2024, compared to -$7.0 million in Q3 2024 and -$4.4 million in Q2 2024.